Study
| Prospective, multicenter, single-arm, phase II cohort study [HD21 trial, NCT02661503] |
| Older patients with advanced-stage classic Hodgkin lymphoma aged 61-75 years |
| 4-6 cycles of PET-guided BrECADD based on PET/CT remission status at PET2 (n=83) |
Efficacy
| CR: 82% [72-90] |
| 2-yr PFS: 91.5% [85-98] |
| 2-yr OS: 90.8% [84-98] |
Safety
| Grade >=3 AE: leukopenia (96%), thrombocytopenia (86%), anemia (69%), febrile neutropenia (55%) |
| No treatment-related mortality |
J Clin Oncol. Published online July 17, 2025.
http://doi.org/10.1200/JCO-25-00439
Reviewed by Elvin Chalabiyev, MD on Sep 3, 2025
